SAB Biotherapeutics Inc. (SABS)
NASDAQ: SABS
· Real-Time Price · USD
2.48
0.14 (5.98%)
At close: Oct 09, 2025, 11:00 AM
5.98% (1D)
| Bid | 1.85 |
| Market Cap | 25.82M |
| Revenue (ttm) | -410 |
| Net Income (ttm) | -37.06M |
| EPS (ttm) | -3.99 |
| PE Ratio (ttm) | -0.62 |
| Forward PE | -2.27 |
| Analyst | Buy |
| Dividends | n/a |
| Ask | 3.11 |
| Volume | 210,955 |
| Avg. Volume (20D) | 1,539,415 |
| Open | 2.48 |
| Previous Close | 2.34 |
| Day's Range | 2.43 - 2.60 |
| 52-Week Range | 1.00 - 6.60 |
| Beta | 0.55 |
| Ex-Dividend Date | n/a |
About SABS
undefined
Industry n/a
Sector n/a
IPO Date n/a
Employees NaN
Stock Exchange n/a
Ticker Symbol SABS
Website n/a
Analyst Forecast
According to 0 analyst ratings, the average rating for SABS stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.
Stock ForecastsSAB Biotherapeutics Inc. is scheduled to release its earnings on
Nov 5, 2025,
after market closes.
Analysts project revenue of ... Unlock content with Pro Subscription
Analysts project revenue of ... Unlock content with Pro Subscription
3 weeks ago
+20%
SAB Biotherapeutics shares are trading higher. Lee...
Unlock content with
Pro Subscription
2 months ago
-3.33%
SAB Biotherapeutics shares are trading lower after HC Wainwright & Co. cut its price target on the stock from $10 to $9.
